s/demishassabisCANCER DRUGS•Apr 22
129
votes
4.3k
seen
Daraxonrasib in pancreatic cancer lands rare ASCO plenary slot
A Phase 3 pancreatic cancer drug just got one of ASCO's few plenary slots, which is usually where practice-changing data shows up.
RASolute 302 is testing daraxonrasib in previously treated metastatic pancreatic cancer, a setting with very few effective options after first-line therapy fails. The update is that ASCO locked it into the plenary session, meaning full data lands in the highest-visibility spot at the May meeting, not a side track.
Ahead of that, the number making the rounds is survival around 2x standard expectations. That builds on earlier KRAS momentum for Revolution Medicines, but this is the first time the pancreatic program is positioned like a top-tier result rather than just promising signal.
RASolute 302 is testing daraxonrasib in previously treated metastatic pancreatic cancer, a setting with very few effective options after first-line therapy fails. The update is that ASCO locked it into the plenary session, meaning full data lands in the highest-visibility spot at the May meeting, not a side track.
Ahead of that, the number making the rounds is survival around 2x standard expectations. That builds on earlier KRAS momentum for Revolution Medicines, but this is the first time the pancreatic program is positioned like a top-tier result rather than just promising signal.
Timeline3
Apr 21
ASCO 2026 abstract titles indicated RASolute 302 would be presented in the plenary session.
Apr 21
Revolution Medicines said it would present detailed Phase 3 RASolute 302 results for daraxonrasib at the ASCO Annual Meeting plenary session.
May 31
ASCO scheduled the plenary presentation of the pivotal Phase 3 RASolute 302 trial results.
0 comments
Apr 22